PROTHENA CORPORATION PUBLIC LIMITED COMPANY Proceeds from Common Stock Issued
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) reported Proceeds from Common Stock Issued of $78.05 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-25.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2022-02-25
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY proceeds from issuance of common stock for the quarter ending 2021-03-31 was $78.37M.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY proceeds from issuance of common stock for the quarter ending 2020-03-31 was $0.00.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY proceeds from issuance of common stock for the quarter ending 2018-12-31 was $0.00.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY proceeds from issuance of common stock for the quarter ending 2018-09-30 was $0.00.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY proceeds from issuance of common stock for fiscal 2021 was $78.05M.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY proceeds from issuance of common stock for fiscal 2020 was $0.00.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY proceeds from issuance of common stock for fiscal 2019 was $0.00.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY proceeds from issuance of common stock for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|
| 2021-12-31 | $78.05M 10-K · filed 2022-02-25 | |||
| 2021-03-31 | $78.37M 10-Q · filed 2021-05-11 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-02-25 | |||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-25 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | $0.00 derived: sum of 2 quarters · filed 2020-03-03 | $0.00 derived: sum of 3 quarters · filed 2020-03-03 | $0.00 10-K · filed 2020-03-03 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $0.00 derived: sum of 2 quarters · filed 2018-11-06 | $0.00 10-Q · filed 2018-11-06 | $0.00 derived: sum of 4 quarters · filed 2020-03-03 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $0.00 10-Q · filed 2018-08-07 | $0.00 derived: sum of 3 quarters · filed 2020-03-03 | $0.00 derived: sum of 4 quarters · filed 2020-03-03 |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-09 | $0.00 derived: sum of 2 quarters · filed 2020-03-03 | $0.00 derived: sum of 3 quarters · filed 2020-03-03 | -$98.00K derived: sum of 4 quarters · filed 2020-03-03 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | $0.00 derived: sum of 2 quarters · filed 2020-03-03 | -$98.00K derived: sum of 3 quarters · filed 2020-03-03 | $150.32M 10-K · filed 2020-03-03 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$98.00K derived: sum of 2 quarters · filed 2018-11-06 | $150.32M 10-Q · filed 2018-11-06 | $150.32M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-06-30 | -$98.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $150.32M 10-Q · filed 2018-08-07 | $150.32M derived: sum of 3 quarters · filed 2019-03-15 | $150.32M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-03-31 | $150.42M 10-Q · filed 2018-05-09 | $150.42M derived: sum of 2 quarters · filed 2019-03-15 | $150.42M derived: sum of 3 quarters · filed 2019-03-15 | $150.41M derived: sum of 4 quarters · filed 2019-03-15 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $0.00 derived: sum of 2 quarters · filed 2019-03-15 | -$8.00K derived: sum of 3 quarters · filed 2019-03-15 | $128.78M 10-K · filed 2019-03-15 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$8.00K derived: sum of 2 quarters · filed 2017-11-07 | $128.78M 10-Q · filed 2017-11-07 | $128.64M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-06-30 | -$8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $128.78M 10-Q · filed 2017-08-09 | $128.64M derived: sum of 3 quarters · filed 2018-02-26 | $128.64M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-03-31 | $128.78M 10-Q · filed 2017-05-09 | $128.65M derived: sum of 2 quarters · filed 2018-02-26 | $128.65M derived: sum of 3 quarters · filed 2018-02-26 | $260.13M derived: sum of 4 quarters · filed 2018-02-26 |
| 2015-12-31 | -$140.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | -$140.00K derived: sum of 2 quarters · filed 2018-02-26 | $131.34M derived: sum of 3 quarters · filed 2018-02-26 | $131.34M 10-K · filed 2018-02-26 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | $131.48M derived: sum of 2 quarters · filed 2016-11-02 | $131.48M 10-Q · filed 2016-11-02 | $131.44M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-06-30 | $131.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-02 | $131.48M 10-Q · filed 2016-08-02 | $131.44M derived: sum of 3 quarters · filed 2017-02-27 | $146.05M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-03-31 | $0.00 10-Q · filed 2016-05-04 | -$43.00K derived: sum of 2 quarters · filed 2017-02-27 | $14.57M derived: sum of 3 quarters · filed 2017-02-27 | |
| 2014-12-31 | -$43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $14.57M derived: sum of 2 quarters · filed 2017-02-27 | $117.35M 10-K · filed 2017-02-27 | |
| 2014-09-30 | $14.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | $117.39M 10-Q · filed 2015-11-02 | ||
| 2014-06-30 | $102.78M 10-Q · filed 2015-08-05 | |||
| 2013-12-31 | $84.53M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $84.53M derived: sum of 2 quarters · filed 2016-02-25 | $84.53M 10-K · filed 2016-02-25 | |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $0.00 10-Q · filed 2014-11-04 | ||
| 2013-06-30 | $0.00 10-Q · filed 2014-08-05 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-03-13 | |||
| 2011-12-31 | $0.00 10-K · filed 2014-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |